Ketamine for
General Chronic Pain
Targeting the neurological amplifier driving pain — not just the pain itself
Ketamine for chronic pain in Baltimore costs $1,499.99 per session ($1,125 for Vitality Circle members) and is delivered as anesthesiologist-led care, under the medical direction of Dr. Brijen Joshi MD, a Johns Hopkins anesthesiologist, with a Certified Registered Nurse Anesthetist (CRNA) on-site — evaluated for persistent pain lasting more than three months that hasn't responded to conventional treatment. Ketamine's primary mechanism is NMDA receptor blockade, which resets central sensitization — the neurological amplification system in the spinal cord and brain that generates and magnifies pain signals disproportionate to any underlying tissue damage. For many chronic pain patients, the nervous system itself has become the primary pain generator, and ketamine targets that neurological driver directly. All chronic-pain use of IV ketamine is off-label — a legal, standard medical practice — and self-pay, with an itemized superbill you can file with your insurance.
"The team is extremely professional, compassionate and knowledgeable — they take the time to explain the process thoroughly and care about your well-being throughout." — Google review, Vita Nova patient
LegitScript CertifiedMon–Fri: 1PM–8PM · Sat: 10AM–2PM
513 Bayview Blvd, Canton Baltimore MD 21224
(443) 563-1059
Tell Us About Your Situation
Answer a few quick questions — our clinical team reaches out within 1 business day to discuss whether ketamine therapy may be right for you.
Your information is confidential. A clinical team member follows up within 1 business day.
When Pain Becomes the Condition Itself
General chronic pain is not a single disease — it is a state in which pain has persisted beyond the expected healing period and has become self-sustaining. For many patients, the nervous system has reorganized around pain, generating and amplifying pain signals independently of any ongoing tissue damage or injury. The original cause may have resolved, but the neurological pain system has been permanently altered.
Chronic pain is formally defined as pain persisting for more than three months. When pain is refractory, widespread, or disproportionate to structural findings, central sensitization is typically the primary driver.
Primary chronic pain occurs in one or more regions of the body, is associated with significant emotional distress or functional disability, and cannot be better explained by another chronic condition. This includes conditions like fibromyalgia, complex regional pain syndrome (CRPS), and chronic widespread pain. The nervous system has become the pain generator — not peripheral tissue.
Secondary chronic pain arises from or alongside a known condition — arthritis, post-surgical pain, neuropathy, inflammatory disease, or injury — but has developed a neurological self-sustaining component that persists beyond the underlying condition's activity. Treating only the original condition may leave the central sensitization intact, which is why many patients continue to have significant pain even after the primary condition is treated or resolved.
Why Your Pain May Persist — Even When Nothing Is "Wrong"
One of the most clinically important and least explained phenomena in chronic pain is the persistence of severe pain in the absence of ongoing tissue damage. Pain may have spread far beyond the original injury site. Imaging may show nothing — or findings that do not match the pain severity. This is the neurological signature of central sensitization.
The window during which acute pain transitions to chronic pain — driven by NMDA receptor hyperactivity in the spinal cord and brain that progressively lowers pain thresholds and amplifies signals. Once established, central sensitization is largely self-sustaining. (Woolf CJ, 2011; Pain)
Central sensitization is a state of neurological hyperexcitability where NMDA receptors in the spinal cord dorsal horn and brain amplify incoming pain signals far beyond what any peripheral tissue damage predicts. In this state, normally non-painful stimuli produce pain (allodynia), pain spreads beyond the original injury site, and the nervous system generates pain largely independently of what is happening in peripheral tissues.
Ketamine is the most direct pharmacological tool available for resetting central sensitization. As an NMDA receptor antagonist, it blocks the receptors responsible for maintaining the hyperexcitable state — interrupting the pain amplification loop directly. A series of infusions may produce a lasting reset of spinal cord excitability thresholds.
Two Mechanisms — NMDA Blockade & Antidepressant Synergy
Ketamine's analgesic effect in chronic pain operates through two complementary pathways particularly relevant for patients with co-occurring depression, PTSD, or treatment-resistant mood disorders alongside their pain.
- Blocks NMDA receptors in the spinal cord dorsal horn — directly interrupting wind-up, the progressive amplification of pain signals with repeated stimulation
- A series of infusions may produce lasting reduction in spinal cord excitability — not just suppressing pain during the infusion but potentially resetting the hyperexcitable state
- Addresses pain that has spread beyond the original injury site or persists after structural resolution — by targeting the central nervous system rather than peripheral tissue
- Does not require a specific peripheral diagnosis — central sensitization is the mechanism regardless of the original pain source
- Reduces allodynia and hyperalgesia — the neurological hypersensitivity states characteristic of established central sensitization
- Chronic pain and depression share overlapping NMDA-mediated neurological pathways — treating one frequently improves the other through shared mechanisms
- Restores prefrontal descending pain inhibition — the brain's natural analgesic system that suppresses pain signals from the spinal cord, which is impaired in both chronic pain and depression
- Rapidly reverses synaptic deficits in prefrontal and limbic circuits — producing rapid antidepressant effects that themselves reduce pain through improved descending inhibition
- Particularly relevant for patients with co-occurring depression, PTSD, or anxiety alongside chronic pain — a common clinical presentation. See our co-occurring depression & chronic pain page
Who Vita Nova Evaluates for General Chronic Pain
Clinical evaluation is required before any care pathway is offered. Not all patients are candidates — the evaluation reviews pain history, prior treatments, current medications, contraindications, and overall clinical profile before any recommendation is made.
Patients evaluated at Vita Nova for general chronic pain typically share one or more of the following clinical characteristics. These are not requirements — they are common patterns that suggest central sensitization may be a primary driver and that ketamine evaluation may be appropriate.
Pain Characteristics
- Pain persisting beyond 3 months despite treatment
- Pain disproportionate to structural findings on imaging
- Widespread or multi-site pain
- Pain that has spread beyond the original injury site
- Allodynia — pain from normally non-painful stimuli
- Pain persisting after a structurally successful procedure
Treatment History
- Inadequate response to NSAIDs, opioids, or anticonvulsants
- Failed nerve blocks, epidural injections, or procedures
- Physical therapy with limited sustained benefit
- Multiple specialist evaluations without resolution
- Co-occurring depression, anxiety, or PTSD alongside pain
- Seeking a non-opioid pathway for ongoing pain management
Chronic Pain Conditions Evaluated at Vita Nova
Vita Nova evaluates ketamine therapy across a range of specific chronic pain diagnoses — each with its own clinical rationale and mechanistic basis.
OA and inflammatory arthritis (RA, psoriatic, AS) — central sensitization amplifies joint pain far beyond structural damage. Ketamine resets the amplifier, not the joint.
Persistent lumbar or thoracic pain — particularly where pain has become disproportionate to structural findings, spread beyond the original site, or persisted after surgical intervention.
Widespread musculoskeletal pain, fatigue, and cognitive symptoms — a prototypical central sensitization condition with no peripheral structural cause. NMDA mechanism directly relevant.
Chronic migraine involves central sensitization of trigeminal pain pathways — NMDA hyperactivity drives the progressive lowering of headache thresholds in frequent sufferers.
Diabetic neuropathy, peripheral neuropathy, CRPS — nerve damage producing burning, shooting, or electric pain through ectopic nerve firing and central sensitization.
Chronic pelvic pain syndrome — strongly associated with central sensitization, where NMDA-mediated neurological amplification drives persistent pelvic pain independent of ongoing tissue pathology.
Persistent pain after technically successful surgery — central sensitization established perioperatively that has become self-sustaining independently of the surgical site's healing status.
Persistent sciatic nerve pain — particularly where pain has developed a central sensitization component that maintains symptoms beyond the original disc or nerve root pathology.
Widespread inflammatory pain where NMDA-mediated central amplification adds to the peripheral inflammatory burden — ketamine targets the central sensitization component that anti-inflammatory treatment alone does not reach.
The Research Behind Ketamine for Chronic Pain
The evidence base for ketamine in chronic pain draws from the central sensitization literature, clinical trials in specific pain conditions, and mechanistic research establishing NMDA receptors as the primary driver of chronic pain amplification.
The definitive review establishing central sensitization as a major mechanism in chronic pain — documenting NMDA receptor hyperactivity as the primary driver of pain amplification, allodynia, hyperalgesia, and the spread of pain beyond original injury sites. Provides the foundational mechanistic rationale for NMDA-targeted ketamine therapy in refractory chronic pain conditions.
Systematic review of ketamine's efficacy for chronic pain including neuropathic pain, fibromyalgia, phantom limb pain, and complex regional pain syndrome — finding clinically meaningful pain reduction across multiple refractory chronic pain conditions with infusion protocols. Supports subanesthetic ketamine infusions as a viable intervention for treatment-resistant chronic pain.
Joint consensus guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists on IV ketamine infusions for chronic pain — covering patient selection, contraindications, subanesthetic dosing ranges, and monitoring. The strongest evidence supports use in complex regional pain syndrome, with weaker but positive evidence for other neuropathic and refractory pain conditions. These guidelines inform the physician-led, monitored infusion protocol used at Vita Nova.
Foundational paper establishing NMDA receptors as the central mechanism of pain plasticity — demonstrating how repeated nociceptive input produces long-term changes in spinal cord neuron excitability that maintain chronic pain independently of peripheral input. The mechanistic basis for all NMDA-targeted pain interventions including ketamine.
Meta-analysis documenting that depression is present in 52% of chronic pain patients — and that the co-occurrence reflects shared NMDA-mediated neurobiological pathways. Patients with co-occurring depression and chronic pain have significantly worse pain outcomes. Supports the dual-mechanism rationale for ketamine targeting both conditions simultaneously.
General Chronic Pain Pricing at Vita Nova Baltimore
| Service | Non-Member | Vitality Circle Member | Saving |
|---|---|---|---|
| Ketamine — Chronic Pain / session Off-Label | $1,499.99 | $1,125 | $374.99/session |
| Relief Series — 4 infusions (+4 complimentary hydration IVs) | $5,699.96 | $4,500 | +4 hydration IVs |
| Vitality Circle Membership / month | — | $99.99/month | Includes pain & MH discounts |
Self-pay, with a superbill. Vita Nova is self-pay for ketamine and provides an itemized superbill you can file with your insurance. Every session is delivered as anesthesiologist-led care, under the medical direction of Dr. Brijen Joshi MD, with a Certified Registered Nurse Anesthetist (CRNA) on-site, in a private room with continuous cardiac and blood-pressure monitoring. Chronic-pain infusions use higher doses over longer sessions — typically two to four hours — and a driver is required after every session. The Relief Series of four infusions includes four complimentary hydration IVs. HSA/FSA accepted; Community Heroes discounts available. Number of sessions determined individually. Pricing August 2026 — subject to change. Full pricing guide →
Complementary Treatments Supporting Chronic Pain Relief
Several wellness services at Vita Nova address physiological factors that amplify chronic pain — including NMDA receptor sensitization, cellular energy deficits in neural tissue, inflammatory cytokine load, and magnesium and vitamin D deficiencies that worsen pain amplification.
Magnesium naturally modulates NMDA receptor sensitivity — directly relevant to ketamine's central sensitization mechanism. Magnesium deficiency increases NMDA excitability, worsening neurological pain amplification.
NAD+ supports mitochondrial energy in pain-processing neural circuits — cellular energy restoration supports the neural plasticity that ketamine's synaptogenic mechanism initiates. Relevant for pain patients with fatigue and cognitive impairment.
High-dose IV Vitamin C reduces oxidative stress and pro-inflammatory cytokine load — particularly relevant for chronic pain patients with inflammatory components. Antioxidant support for neural tissue under chronic stress.
Vitamin D3 deficiency is extremely common in chronic pain patients — particularly those with limited mobility. Low D3 is associated with increased pain severity and central sensitization. IM D3 achieves therapeutic blood levels rapidly.
Clinical note: These wellness services are not treatments for chronic pain and do not replace physician-directed pain management. Always discuss supplemental therapy with your treating physician.
Special Pricing for Those Who Serve
Veterans, first responders, and healthcare workers carry elevated rates of chronic pain from the physical and occupational demands of service. Decades of pain should not be compounded by cost barriers to care.
General Chronic Pain & Ketamine — Questions Answered
Common questions from patients with refractory or widespread chronic pain evaluating ketamine therapy in Baltimore.
Years of Chronic Pain
Deserve a Different Approach —
When conventional pain management hasn't been enough, ketamine's NMDA mechanism targets the neurological amplifier driving your pain — not just another peripheral treatment. Off-label, self-pay with an itemized superbill you can file with your insurance. No commitment required. Community Heroes discounts available.
Canonical URL: https://vitanovawellnessclinic.com/ketamine-for-chronic-pain-baltimore/ · Last reviewed August 2026
